Comparison between burning mouth syndrome patients with and without psychological problems

Kim, M.-J.; Kim, J.; Kho, Hong‐Seop

doi:10.1016/j.ijom.2018.02.001

Cited by 31 publications

(49 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All participants underwent oral examination, panoramic radiography, simplified psychological evaluation (Symptom Checklist‐90‐Revised, SCL‐90‐R), laboratory tests, measurement of whole salivary flow rates, evaluation of clinical characteristics using a BMS questionnaire, and interview. The whole procedures including SCL‐90‐R, blood examination and measurement of salivary flow rates were described in detail in our previous studies 12,13 . A single doctor (HSK) performed all evaluation procedures.…”

Section: Methodsmentioning

confidence: 99%

Oral health‐related quality of life and associated factors in patients with burning mouth syndrome

Choi

Kim

Kho

2020

J of Oral Rehabilitation

Self Cite

View full text Add to dashboard Cite

Objective The purpose of this study was to assess oral health‐related quality of life (OHRQoL) in patients with burning mouth syndrome (BMS) and to identify clinical factors associated with OHRQoL. Methods Fifty‐seven patients with BMS (56.4 ± 10.7 years) participated in the study. Patients underwent oral examination, laboratory tests, psychological evaluation, measurement of salivary flow rates and evaluation of clinical characteristics using a BMS questionnaire. The OHRQoL of patients was assessed using the Oral Health Impact Profile‐14 (OHIP‐14). Results The OHIP‐14 score for patients with BMS was 38.6 ± 12.8. Patients had higher scores for the psychological discomfort and physical pain dimensions of the OHIP‐14. The intensity of taste disturbance or xerostomia symptoms (β = 0.464, P < .001), worry about symptoms (β = 0.307, P = .020), and results of psychological evaluation (β = 0.311, P = .026) were significantly associated with OHIP‐14 score. Multiple linear regression showed that the intensity of taste disturbance or xerostomia symptoms was significantly associated with decreased OHRQoL (β = 0.637, P = .026). Conclusions This study suggests that severity of taste disturbance or xerostomia is an important factor that influences OHRQoL in patients with BMS.

show abstract

Section: Methodsmentioning

confidence: 99%

Oral health‐related quality of life and associated factors in patients with burning mouth syndrome

Choi

Kim

Kho

2020

J of Oral Rehabilitation

Self Cite

View full text Add to dashboard Cite

show abstract

“…Comprehensive clinical examination procedures included an oral examination, interview, radiographic examination (panoramic view), measurement of the whole salivary flow rate, laboratory test, a simplified psychological evaluation (Symptom Checklist-90-Revision, SCL-90-R), and a BMS questionnaire as described in our previous study [23]. The…”

Section: Comprehensive Clinical Examinationsmentioning

confidence: 99%

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Kim

Kho

2019

JOMP

Self Cite

View full text Add to dashboard Cite

Purpose: Venlafaxine and duloxetine have been shown to be effective in the treatment of neuropathic pain disorders. However, knowledge about the efficacy of venlafaxine and duloxetine on burning mouth syndrome (BMS) is still insufficient. The purpose of this study was to investigate the efficacy of venlafaxine and duloxetine on refractory BMS patients. Methods:Twelve refractory BMS patients who were prescribed venlafaxine or duloxetine were included in this study. These patients did not respond to previous administration of clonazepam, alpha-lipoic acid, gabapentin, and nortriptyline. All participants were the primary type of BMS patients who had no local and systemic factors related to the oral burning sensation. The intensities of oral symptoms following venlafaxine or duloxetine administration were compared with those before administration and at baseline.Results: Venlafaxine and duloxetine were prescribed to four and nine patients, respectively. One patient was prescribed both medications in turn. Among them, only two patients showed improvement of oral symptoms without side effects. In the other ten patients, symptoms failed to improve. Six of them reported that the drug was ineffective, and four of them stopped taking the medications on their own due to intolerable side effects, such as insomnia, constipation, drowsiness, dizziness, and xerostomia.Conclusions: Venlafaxine and duloxetine may only relieve oral symptoms in a minority of refractory BMS patients. Further large-scale studies are needed to determine the potential clinical factors that could predict the efficacy of venlafaxine and duloxetine.

show abstract

“…336 Patients with BMS frequently suffer from concurrent psychopathology, such as depression and anxiety, and neurological disorders, such as neuropathy or neuralgia, and exhibit a distorted circadian rhythm with sleep deprivation. 336,338,339 Most patients with BMS are female. 336,338,340,341 Promising advances have been made in the field of BMS management.…”

Section: Oral Medicine and Oral And Maxillofacial Surgerymentioning

confidence: 99%

“…336,338,339 Most patients with BMS are female. 336,338,340,341 Promising advances have been made in the field of BMS management. Topical and systemic therapeutic options are available.…”

Section: Oral Medicine and Oral And Maxillofacial Surgerymentioning

confidence: 99%

Annual review of selected scientific literature: A report of the Committee on Scientific Investigation of the American Academy of Restorative Dentistry

Cagna

Donovan

McKee³

et al. 2019

The Journal of Prosthetic Dentistry

View full text Add to dashboard Cite

Comparison between burning mouth syndrome patients with and without psychological problems

Cited by 31 publications

References 35 publications

Oral health‐related quality of life and associated factors in patients with burning mouth syndrome

Oral health‐related quality of life and associated factors in patients with burning mouth syndrome

Treatment Outcomes of Venlafaxine and Duloxetine in Refractory Burning Mouth Syndrome Patients

Annual review of selected scientific literature: A report of the Committee on Scientific Investigation of the American Academy of Restorative Dentistry

Contact Info

Product

Resources

About